Skip to main content
SpringerLink
Log in

Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Matrix metalloproteases (MMP) are a family of enzymes that contribute to the degradation of the extracellular matrix. The destruction of the extracellular matrix eventually leads to tumour invasion, metastasis and angiogenesis. Realising this mechanism of action, there is tremendous potential for inhibitors of MMP in cancer therapy. Extensive preclinical data have shown that administration of matrix metalloprotease inhibitors (MMPI) to different animal models results in a reduction in primary tumour growth as well as in the number and size of metastatic lesions. Based on promising preclinical studies, synthetic MMPI have been developed and taken into clinical trials. These include marimastat, BAY-129566, CGS-27023A, prinomastat (AG-3340), BMS-275291 and metastat (COL-3). These drugs are all in different stages of clinical development, ranging from phase I to III. In general, musculoskeletal problems, such as joint stiffness and pain in hands, arms and shoulders seem to affect most patients in varying degrees, depending on the dose and type of compound administered. In addition to single agent therapy, several MMPI have entered trials of combination therapy. The objective of combining chemotherapy with an MMPI is to potentiate tumour cytotoxicity as well as to reduce the size and number of metastatic lesions. Several compounds have entered phase III combination therapy trials, but it is still too early to report any data. There is ongoing research in correlating biological end-points, such as levels of MMP and markers of angiogenesis with clinical response. As the field of MMP and their inhibitors continues to mature, its role in cancer therapeutics will be better defined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

Similar content being viewed by others

References

  1. Wojtowcz-Praga SM, Dickerson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. InvestNew Drugs 1997; 15: 61–75

    Article  Google Scholar 

  2. Seiki M. Membrane type-matrix metalloproteinase and tumor invasion. Curr Top Microbiol Immunol 1996; 213(Pt 1): 23–32

    Article  PubMed  CAS  Google Scholar 

  3. Chambers AF. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89(17): 1260–70

    Article  PubMed  CAS  Google Scholar 

  4. Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation, and biological functions. Eur J Cell Biol 1997; 74: 111–22

    PubMed  CAS  Google Scholar 

  5. Gross J. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A 1962; 48: 1014–22

    Article  PubMed  CAS  Google Scholar 

  6. Takino T, Sato H, Shinagawa A. Identification of the second membrane type-matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library.MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem 1995; 270: 23013–20

    Article  PubMed  CAS  Google Scholar 

  7. Hembry RM, Bagga MR, Reynolds JJ. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 1995; 54: 25–32

    Article  PubMed  CAS  Google Scholar 

  8. Koolwijk P, Miltenburg AM, van Erck MG, et al. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J Rheumatol 1995; 22 385–93

    PubMed  CAS  Google Scholar 

  9. Bailey CJ, Hembry HM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Chron’s disease and normal intestine. J Clin Pathol 1994; 47: 113–16

    Article  PubMed  CAS  Google Scholar 

  10. Milani S, Herbst H, Schuppan D, et al. Differential expression of matrix metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994; 144: 528–37

    PubMed  CAS  Google Scholar 

  11. Newman KM, Malon AM, Shin RD, et al. Matrix metalloproteinases in abdominal aortic aneursym: characterization, purification, and their possible sources. Connec Tissue Res 1994; 30: 265–76

    Article  CAS  Google Scholar 

  12. Irizarry E, Newman KM, Gandhi RH, et al. Demonstration of interstitial collagenase in abdominal aortic aneursym disease. J Surg Res 1993; 54: 571–4

    Article  PubMed  CAS  Google Scholar 

  13. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP2 and MMP-9. J Invest Dermatol 1993; 101: 64–8

    Article  PubMed  CAS  Google Scholar 

  14. Parsons SL, Watson SA, Brown PD, et al. Matrix metalloproteinases. Br J Surg 1997; 84: 160–6

    Article  PubMed  CAS  Google Scholar 

  15. Nomura H, Sato H, Sciki M, et al. Expression of membrane type-matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 3263–6

    PubMed  CAS  Google Scholar 

  16. Gress TM, MUller-Pillasch F, Lerch MM, et al. Expression and in-situ localisation of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407–13

    Article  PubMed  CAS  Google Scholar 

  17. Nuovo GJ, MacConnell PB, Simsir A, et al. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNA and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55: 267–75

    PubMed  CAS  Google Scholar 

  18. Davies B, Waxman J, Wasan H, et al. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53: 5365–9

    PubMed  CAS  Google Scholar 

  19. Brown PD, Bloxidge RE, Stuart NS, et al. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Inst 1993; 85: 574–8

    Article  PubMed  CAS  Google Scholar 

  20. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370: 61–5

    Article  PubMed  CAS  Google Scholar 

  21. Fiebig H, Klostermeyer A, Schüler JB. Characterization of matrix metalloproteinases in 47 human tumor xenografts show high expression of MMP2 in melanomas and sarcomas [abstract no. 3058]. Proceedings of the 90th Annual Meeting of the American Association for Cancer Research; 1999 Apr 10–14; Philadelphia (PA)

  22. Davies B, Brown PD, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53: 2087–91

    PubMed  CAS  Google Scholar 

  23. Wang X, Fu X, Brown PD, et al. Matrix metalloproteinase inhibitor BB-94 (batimistat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54: 4726–8

    PubMed  CAS  Google Scholar 

  24. Chirivi RG, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 59: 460–4

    Article  Google Scholar 

  25. Sledge GW, Qulali M, Goulet R, et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995; 87: 1546–50

    Article  PubMed  CAS  Google Scholar 

  26. Gu B, Wu DZ, Lu HZ, et al. Batimastat potentiates the antitumor activity of docetaxel in mouse forestomach carcinoma model [abstract no. 3886]. Proceedings of the 90th Annual Meeting of the American Association for Cancer Research; 1999 Apr 10–14; Philadelphia (PA)

  27. Koop S, MacDonald IC, Luzzi K, et al. Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res 1995; 55: 2520–3

    PubMed  CAS  Google Scholar 

  28. Flynn C, Bull C, Eberwein D, et al. Anti-metastatic activity of BAY 12-9566 in a human colon carcinoma HCT 116 orthotopic model [abstract no. 2057]. Proceedings of the 89th Annual Meeting of the American Association for Cancer Research; 1998 Mar 28–Apr 1; New Orleans (LA), 301

  29. Rabbani S, Harakida P, Guo YJ, et al. A synthetic matrix metalloprotease inhibitor decreases tumor growth and metastases by inhibiting angiogenesis and promoting apoptosis in a syngeneic model of rat prostate cancer in vivo [abstract no. 3025]. Proceedings of the 90th AnnualMeeting of the American Association for Cancer Research; 1999 Apr 10–14; Philadelphia (PA)

  30. Shalinsky DR, Brekken J, Zou, et al. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Invest New Drugs 1998–99; 16(4): 303–13

    PubMed  CAS  Google Scholar 

  31. Boasberg P, Harbaugh, Eisenberger M. Marimastat in patients with hormone refractory prostate cancer: a dose-finding study [abstract no. 1126]. Proceedings of the 33th Annual Meeting of the American Society of Clinical Oncology; 1997 May 17–20; Denver (CO), 316a

  32. Bazzett L, Taylor DD, Wan TC. Significance of matrix metalloproteinases in urine of patients with endometrial and ovarian carcinoma [abstract no. 1430].Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18: 370A

    Google Scholar 

  33. Koshiba T, Hosotani R, Wada M, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998; 82: 642–50

    Article  PubMed  CAS  Google Scholar 

  34. Costa L, Deniers LM, Speicher T. Biochemical markers of bone turnover correlate with the extent of metastatic bone disease [abstract no.2375]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18: 615A

    Google Scholar 

  35. Lhotak S, Elavathil LJ, Duivenvoorden W. Immunolocalization of matrix metalloproteinases in human bone metastases of breast carcinoma [abstract no. 461]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18: 121A

    Google Scholar 

  36. Macaulay VM, O’Byrne KJ, Saunders MP, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999: 5: 513–20

    PubMed  CAS  Google Scholar 

  37. Millar A. 360 Patient meta-analysis of studies of marimastat.A novel matrix metalloproteinase inhibitor. Ann Oncol 1996; 7 Suppl. 5: 123

    Google Scholar 

  38. Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998; 16(6): 2150–6

    PubMed  CAS  Google Scholar 

  39. British Biotech. Results of marimastat study 145 in gastric cancer [press release]. Oxford: British Biotech, 1999 Aug 24

    Google Scholar 

  40. Rosemurgy A, Buckels J, Charnley R. Arandomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer [abstract no. 1005]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18: 261A

    Google Scholar 

  41. Gradishar W, VonRoenn J, Cobleigh M, et al. A phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer [abstract no. 476]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18: 125A

    Google Scholar 

  42. Adams M, Thomas H. A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer [abstract no. 838]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–19; Los Angeles (CA), 17: 217A

    Google Scholar 

  43. Rozencweig M. Randomized trials of carboplatin versus cisplatin in advanced ovarian cancer. In: Bunn PA, Canetta R, Ozols RF, et al., editors. Carboplatin (JM-8) current perspectives and future directions. Philadelphia (PA): Saunders, 1990: 175–86

    Google Scholar 

  44. Carmichael J, Ledermann PJ, Woll PJ, et al. Phase Ib study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer [abstract no. 888]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–19; Los Angeles (CA), 17: 232A

    Google Scholar 

  45. Anderson I, Supko J, Eder J. Pilot pharmacokinetic study of marimastat (MAR) in combination with carboplatin (C)/ paclitaxel (T) in patients with metastatic or locally advanced inoperable non-small cell lung cancer (NSCLC) [abstract no. 719]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18: 187a

    Google Scholar 

  46. Zaknoen S, Wolf R, Cox J. Marimastat in advanced progressive colorectal cancer-a dose finding study [abstract no. 968]. Proceedings of the 33th Annual Meeting of the American Society of Clinical Oncology; 1997 May 17–20; Denver (CO), 273a

  47. Bodurtha A, Eisenhauer E, Steward W. Phase I–II study of marimastat (BB2516) in patients (pts) with metastatic melanoma [abstract no. 1775]. Proceedings of the 33th Annual Meeting of the American Society of Clinical Oncology; 1997 May 17–20; Denver (CO), 493a

  48. O’Reilly S, Mani S, Ratain MJ. Schedules of 5FU and the matrix metalloproteinase inhibitor marimastat (MAR): A phase I study [abstract no. 839]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–19; Los Angeles (CA), 17: 217A

    Google Scholar 

  49. Seymour L, Grochow L, Eckhardt G, et al. Clinical and Pharmacokinetic (PK) results from 4 phase I studies of BAY 12-9566, a novel non-peptidic biphenyl inhibitor of matrix metalloproteases 2,3 & 9. 23rd ESMO Congress; 1998 Nov 6–10; Athens

  50. Tolcher A, Rowinsky EK, Rizzo J. Aphase I and pharmacologic study of the oral matrix metalloproteinase inhibitor, BAY 12-9566 in combination with paclitaxel and carboplatin [abstract no. 617]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18: 160A

    Google Scholar 

  51. Bayer Corporation. Bayer halts trials evaluating MMPI [press release 1999 Sep 24; online]. Available from URL: http://www.bayerus.com/new/division/index.html [Acessed 2000 Apr 11]

  52. Levitt NC, Eskins F, Propper DJ. A phase one pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor [abstract no. 823]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–19; Los Angeles (CA), 17: 213A

    Google Scholar 

  53. Eatock M, Cassidy J, Johnson J. A phase I study of the matrix metalloproteinase inhibitor MM1270 (previously termed CGS27023A) with 5FU and folinic acid [abstract no. 803]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18: 209A

    Google Scholar 

  54. Johnston MR, Mullen JM, Pagura M, et al. AG3340 and carboplatin increase survival in an orthotopic nude rat model of primary and metastatic human lung cancer [abstract no. 1946]. Proceedings of the 90th Annual Meeting of the American Association for Cancer Research; 1999 Apr 10–14; Philadelphia (PA)

  55. Agouron Pharmaceuticals Inc. Investigator’s brochure. San Diego (CA): Agouron Pharmaceuticals Inc., 1999 Oct to Dec 31

  56. D’Olimpio J, Hande K, Collier M. Phase I study of matrix metalloprotease inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors [abstract no. 615]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 160a

  57. Wilding G, Small E, Collier M. Aphase I pharmacokinetic evaluation of the matrix metalloprotease (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer [abstract no.1244]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA), 18: 323A

    Google Scholar 

  58. Rizvi N, Humphrey J, Ness J, et al. A phase I, safety, and pharmacokinetic trial of BMS-275291, a matrix metalloproteinase inhibitor (MMPI), in patients with advanced or metastatic cancer [abstract no. 0726]. Proceedings of the 90th Annual Meeting of the American Association for Cancer Research; 1999 Apr 10–14; Philadelphia (PA)

  59. Rudek M, Figg W, Dyer V, et al. A phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, administered daily in patients with refractory metastatic cancer [abstract no. 3894]. Proceedings of the 91st Annual Meeting of the American Association for Cancer Research; 2000 Apr 1–5; San Francisco (CA)

  60. Brewster M, Lewis EJ, Wilson KL, et al. Ro 32-3555, an orally active collagenase inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum 1998: 41: 1639–44

    Article  PubMed  CAS  Google Scholar 

  61. Lee J, Bone EA, Watson PH, et al. Effect of matrix metalloproteinase (MMP) inhibitor, batimastat, on bone metastasis [abstract no. 2044]. Proceedings of the 89th Annual Meeting of the American Association for Cancer Research; 1998 Mar 28–Apr 1; New Orleans (LA), 299

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, Maryland, 21231, USA

    Elisabeth I. Heath

  2. National Cancer Institute, Rockville, Maryland, USA

    Louise B. Grochow

Authors
  1. Elisabeth I. Heath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louise B. Grochow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabeth I. Heath.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heath, E.I., Grochow, L.B. Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy. Drugs 59, 1043–1055 (2000). https://doi.org/10.2165/00003495-200059050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200059050-00002

Keywords

Search

Navigation